Head and neck cancer trial pulled before it began
NCT ID NCT01326468
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This pilot study aimed to test the safety of adding the drug Temsirolimus (Torisel) to standard chemoradiotherapy for people with advanced head and neck cancer. The goal was to find a safe dose of Temsirolimus when given alongside radiation and other chemotherapy drugs like Cetuximab (Erbitux). However, the study was withdrawn before any participants were enrolled, so no data was collected.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Temsirolimus (Torisel) and Cetuximab (Erbitux)
What this could lead to
If it had worked, this could have pointed toward a more effective treatment for advanced head and neck cancer by adding Temsirolimus to standard therapy.
What could go wrong
The trial was withdrawn before any patients were enrolled, so no results are available. It is unknown whether the combination would have been safe or effective.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.